Top 10 Things to Know About Ketamine

10 Things You Should Know About Ketamine Treatment

Ketamine treatment has received an extraordinary amount of attention. Some descriptions present it as a breakthrough capable of lifting depression within hours. Others focus almost entirely on its history as an anaesthetic or its misuse as a recreational drug.

Understandably, people are left with questions.

Is ketamine a recognised medical treatment or an experimental one? Does receiving it mean being unconscious? Is the experience itself therapeutic? Can it become addictive? And what is the role of psychotherapy if the medicine is responsible for reducing the symptoms?

The honest answer is that ketamine is neither a miracle cure nor simply a dangerous drug repurposed by private clinics. It is a powerful prescription medicine with a long history in healthcare and a developing role in specialist mental-health treatment. Some people experience meaningful improvement after other treatments have failed. Others receive little benefit, find that the improvement does not last, or decide that the experience is not right for them.

Here are ten things worth understanding before forming an opinion about ketamine treatment.

1. Ketamine Is an Established Medicine, but Its Use for Depression Is Different

Ketamine is not a new or untested chemical. It has been used in medicine for decades, principally as an anaesthetic and for pain relief. Its effects depend heavily on the dose and the circumstances in which it is given.

During surgery, ketamine may be used at doses intended to produce anaesthesia. In mental-health treatment, considerably lower doses are normally used. The aim is not to render the person unconscious but to produce a psychiatric and, in some treatment models, psychologically meaningful effect.

There is also an important regulatory distinction. Standard ketamine is a licensed medicine, but it is not licensed in the UK specifically as an antidepressant. A qualified prescriber can nevertheless prescribe a licensed medicine outside the terms of its licence when they judge that this is clinically appropriate. This is commonly known as off-label prescribing, and it places additional responsibility on the prescriber to consider the evidence, alternatives, risks and individual needs of the patient. (GOV.UK)

Esketamine is related to ketamine but is not exactly the same product. It is supplied as a nasal spray under the brand name Spravato and has a UK marketing authorisation for treatment-resistant major depression when used with an SSRI or SNRI antidepressant. However, NICE does not currently recommend it for routine NHS use because of concerns about the clinical and cost-effectiveness evidence presented during its appraisal. (Electronic Medicines Compendium)

The fact that a medicine is prescribed off-label does not mean that its use is automatically unsafe or inappropriate. It does mean that the decision should follow a proper medical assessment and an honest discussion of what is known, what remains uncertain and what other treatments have already been tried.

2. “Ketamine Treatment” Can Mean Several Very Different Things

It is easy to speak about ketamine treatment as though every clinic provides the same intervention. In reality, the phrase covers several routes of administration, dose ranges and treatment philosophies.

Ketamine may be administered intravenously through a controlled infusion, injected into a muscle, taken orally or placed under the tongue. Esketamine is administered through a nasal spray. The route affects how quickly the medicine enters the bloodstream, how predictable its absorption is, how the dose is controlled and how the experience develops.

An intravenous infusion allows the rate of administration to be adjusted while the treatment is taking place. An intramuscular injection is absorbed from the muscle and cannot be slowed down once it has been given. Oral and sublingual ketamine are affected more substantially by digestion and metabolism, which can make absorption less predictable. Nasal esketamine has its own authorised dosing and monitoring requirements.

The setting can differ just as much as the route. Some services use ketamine primarily as a biological treatment for depression. The person receives the medicine, is medically monitored and has their symptoms reviewed, but little or no psychotherapy is provided.

Other programmes combine ketamine with psychological preparation, support during the session and integration therapy afterwards. In these programmes, the altered state may be treated as part of the therapeutic process rather than merely a side effect accompanying the antidepressant response.

Neither approach should be casually presented as identical to the other. A course of medication-focused infusions and a programme of ketamine-assisted psychotherapy may share the same medicine but differ considerably in their aims, structure and the experience of the patient.

When comparing services, it is therefore worth asking exactly what is being offered rather than relying on the broad label of “ketamine therapy.”

3. The Evidence Is Strongest for Rapid Symptom Reduction, Not Guaranteed Recovery

Ketamine became especially interesting to depression researchers because of the speed at which some participants improved.

Conventional antidepressants often require several weeks before their full effect can be assessed. In contrast, clinical trials of intravenous ketamine have repeatedly found that some people with difficult-to-treat depression experience a reduction in symptoms within hours or days. Oxford Health’s specialist ketamine service describes a rapid antidepressant effect across numerous trials involving people who had not responded adequately to several previous antidepressants. (Oxford Health NHS Foundation Trust)

That finding matters. Severe depression can make movement feel almost impossible. If someone becomes less hopeless, less withdrawn or more able to think clearly, even a relatively brief improvement may help them reconnect with treatment and everyday life.

However, “rapid acting” is easily misheard as “rapid cure.”

Researchers commonly distinguish between response and remission. A response usually means that symptoms have reduced substantially. Remission means that symptoms have fallen below a defined threshold. Neither necessarily tells us how long the improvement will last.

Some people do not respond at all. Some experience a partial change. Others improve noticeably and then find that depression begins to return. Even people who initially benefit may later find that continued treatment no longer controls their symptoms as effectively. (Oxford Health NHS Foundation Trust)

This does not make the initial response meaningless. It does mean that early improvement should be understood as one part of a longer clinical picture.

Depression is not simply a number on a rating scale. Recovery may also involve relationships, work, sleep, self-worth, physical health, trauma, isolation and a person’s sense of direction. Ketamine may reduce symptoms sufficiently for work on those areas to become possible, but it cannot be assumed to resolve them automatically.

4. Dose Changes the Nature of the Experience

People often ask what ketamine treatment feels like, but there is no single answer. Dose is one of the factors that can significantly alter the experience.

At lower psychiatric doses, a person may feel relaxed, light, slightly detached or less caught up in their usual thoughts. Their perception of time may change, music may feel more absorbing, and emotions may become easier to approach. In some treatment models, the person remains able to speak with a therapist throughout much of the session.

As the dose increases, the experience may become more immersive. Awareness of the room and body can recede. The person may experience vivid imagery, unusual perspectives, a sense of movement, or a feeling that ordinary boundaries between themselves and the world have softened.

This detachment is often described as dissociation. The word can sound alarming, but dissociation exists on a spectrum. For one person it may feel peaceful or spacious. For another it can feel disorientating or frightening.

Higher doses are not automatically more therapeutic. A dramatic experience is not proof that a better antidepressant or psychological outcome has occurred. Equally, a quiet session is not necessarily an unsuccessful one.

The most appropriate dose depends on the treatment aims, route of administration, physical health, previous response and how the person tolerates the medicine. Side effects are generally more common at higher doses, although individuals vary considerably. (Oxford Health NHS Foundation Trust)

Responsible dosing should therefore be clinically led. It should not become a pursuit of the strongest possible experience or an assumption that the person must lose all awareness of themselves before anything meaningful can happen.

5. Mental-Health Treatment Does Not Usually Mean Being Put Under Anaesthetic

Because ketamine is widely known as an anaesthetic, some people imagine that psychiatric treatment involves being put to sleep.

At the lower doses normally used in depression treatment, people generally remain conscious. They can usually hear sounds in the room and respond when spoken to, although they may feel less connected to their body, surroundings or ordinary sense of identity.

The experience varies enormously.

One person may see colours, shapes or internally generated scenes. Another may remember events from their life or experience strong emotions. Some describe a sense of perspective, as though they can observe their problems without being completely absorbed by them.

Others experience little that feels profound. They may feel physically heavy, mildly intoxicated or simply relaxed. Some find the session pleasant but not especially meaningful. A minority may experience anxiety, nausea, confusion or an uncomfortable sense of losing control.

None of these reactions provides a simple measure of whether the treatment is working.

It is also important to avoid describing every internal experience as a hallucination. Much of what people report is closer to dreamlike imagery, altered perception or an intensified inner world. They usually retain some awareness that the experience is being produced in the context of treatment.

A person’s expectations, emotional state, dose and surroundings can all influence what happens. This is one reason preparation matters. It is helpful to know that there is no correct way to experience ketamine and no requirement to produce a dramatic story afterwards.

The treatment should provide enough structure and reassurance for the person to experience what arises without feeling that they must perform, achieve a breakthrough or please the clinicians supporting them.

6. A Powerful Experience Can Be Meaningful Without Being Literally True

Ketamine can temporarily change the way thoughts, memories and emotions are experienced. Familiar psychological defences may feel less rigid, and connections may appear between events that previously seemed unrelated.

This can be valuable. Someone may recognise how much anger they have kept beneath depression, how isolated they have become, or how an early relationship continues to shape the way they respond to other people.

But altered states also require careful interpretation.

A vivid image is not automatically a recovered memory. A strong conviction felt during a session is not necessarily an objective fact. A person may feel that they have understood their entire life and then find, once the intensity has passed, that the insight needs to be reconsidered.

The most helpful response is often curiosity rather than certainty.

What did the experience bring into awareness? Why might that theme matter? Does it connect with something already known about the person’s history? How does it affect the way they understand their present life?

Psychotherapy can help hold this middle ground. It need not dismiss the experience as meaningless brain activity, but it should not impose a grand interpretation or treat every image as historical truth.

There is also a risk of confusing the emotional force of an experience with lasting change. Someone can feel tremendous love, release or clarity during a session and still return to the same habits afterwards.

The experience may reveal a direction. It cannot walk in that direction for the person.

Its value becomes clearer through what follows: the conversations undertaken, boundaries established, relationships repaired, routines changed and new responses practised when ordinary life resumes.

7. Medical and Psychological Screening Are Central to Safe Treatment

Ketamine treatment should not begin simply because somebody is interested in it and able to pay.

A proper assessment looks beyond the diagnosis of depression. It considers whether ketamine is medically appropriate, whether the psychiatric risks are manageable and whether the person is likely to receive meaningful benefit from the particular programme being offered.

Physical assessment may include blood pressure, cardiovascular history, current medication, liver and urinary health, pregnancy status and relevant blood tests. Ketamine can temporarily increase blood pressure and heart rate, so uncontrolled cardiovascular problems require particular consideration. (Electronic Medicines Compendium)

Psychiatric assessment is equally important. A clinician should consider previous mania, psychosis, dissociation, substance misuse, suicidal risk and whether another diagnosis may better explain the person’s difficulties. Oxford Health, for example, warns of a risk of manic relapse and requires detailed information about previous psychiatric treatment before accepting someone for ketamine treatment. (Oxford Health NHS Foundation Trust)

Assessment should also examine expectations. Someone seeking a single dramatic experience that will remove years of suffering may need a more realistic understanding of what treatment can offer.

In a psychotherapy-based programme, psychological readiness matters too. Can the person communicate when distressed? Do they have sufficient support after treatment? Are there unresolved risks that need stabilising first? Are they prepared to engage in the work surrounding the medicine rather than seeing the dose itself as the whole intervention?

A decision that ketamine is unsuitable is not necessarily a failure of treatment. Sometimes it is evidence that the assessment process is doing its job.

8. Ketamine Has Real Side Effects and Risks

Ketamine may be administered safely in clinical settings, but it should never be presented as risk-free.

Short-term effects can include dizziness, nausea, blurred vision, altered perception, dissociation, anxiety, increased blood pressure and impaired coordination. Some people feel emotionally vulnerable or confused as the effects develop. Most short-term effects settle as the medicine wears off, but appropriate observation remains necessary. (Electronic Medicines Compendium)

People should not drive themselves home after a ketamine session. Even when they feel mentally clear, reaction time, judgement and coordination may remain affected. The treating service should provide clear instructions about driving, work, alcohol, medication and other safety-sensitive activities after treatment.

Longer-term risks are more difficult to quantify because psychiatric treatment protocols vary and long-term data remain limited. Oxford Health explicitly advises patients that ketamine is not licensed for depression and that the effects of prolonged use are not fully known. (Oxford Health NHS Foundation Trust)

Frequent uncontrolled use is associated with much clearer harms, including dependence, cognitive problems, severe bladder and urinary-tract injury, abdominal pain, and liver and bile-duct complications. The 2026 ACMD review describes significant harm among people using ketamine heavily and repeatedly. (GOV.UK)

This does not mean that a limited number of medically supervised sessions carries the same risk as daily recreational use. The dose, frequency, setting and control of access are fundamentally different.

However, a responsible clinical service should not use that distinction to dismiss the potential for harm. It should control dosing, monitor outcomes, review continued treatment and remain willing to stop when the balance between benefit and risk changes.

9. Psychotherapy and Integration Are Not Effects of the Medicine

Ketamine can alter mood, perception and the way a person relates to their thoughts. Psychotherapy is the human process of understanding what those changes mean and how they might be used.

The two should not be confused.

Preparation may explore the person’s history, expectations, fears and treatment goals. It can also help establish how support will be provided if the experience becomes difficult.

During treatment, the therapist’s role depends on the model being used. In some approaches, there may be active conversation. In others, the therapist remains quietly present and intervenes only when needed. Good support does not involve pushing the person towards trauma, directing the content of the experience or insisting that emotional release must occur.

Integration happens afterwards. The person may reflect on memories, feelings or insights that arose, but integration is not merely retelling the session. It asks how the experience connects with ordinary life.

A realisation that a relationship is damaging may require a difficult conversation or a new boundary. A sense of compassion for oneself may need to be practised when shame returns. A temporary desire to reconnect with life has to become an actual phone call, walk, appointment or change in routine.

Ketamine may create a period in which the person feels less rigid, less defended or more able to imagine change. Research into the precise added value and best form of psychotherapy remains less developed than research into ketamine’s short-term antidepressant effects, so claims should remain measured.

The medicine may open an opportunity. Psychotherapy helps the person decide what to do with it.

10. The Quality of the Clinic Matters

Ketamine is not made safe simply by placing it in a pleasant room and calling the experience therapeutic.

A responsible provider should be able to explain who conducts the medical assessment, who prescribes the medicine, who administers it and what happens if a complication occurs. The clinical responsibilities of medical and psychological staff should be clear rather than blurred.

Ask how suitability is decided. Does the clinic obtain relevant medical and psychiatric information? Does it consider previous treatment, cardiovascular health, substance use, mania and psychosis risk? Can it explain why ketamine is being considered rather than simply offering it to anyone who makes contact?

The dosing process should also be transparent. Decisions should be based on clinical aims, safety and individual response, not on pressure to produce an increasingly intense experience.

Monitoring matters. The clinic should be equipped to observe the person appropriately and respond if blood pressure rises, nausea develops or the experience becomes distressing. It should also have clear arrangements for recovery and safe travel home.

Where psychotherapy is offered, ask about the qualifications and experience of the person providing it. Preparation and integration should amount to more than brief conversations added to make a medication service sound holistic.

It is also worth asking what happens when treatment does not work. A trustworthy clinic should be willing to discuss non-response, deterioration and the circumstances in which it would recommend stopping.

Perhaps the most revealing question is whether the service can say no.

A clinic that assesses carefully will sometimes decide that ketamine is not appropriate, that further information is needed or that another form of treatment should come first. That may be disappointing, but it is an essential part of responsible care.

What Matters Most

Ketamine treatment sits in an area where excitement can easily run ahead of evidence.

There are good reasons for the interest. Some people with severe and persistent depression experience improvement after conventional treatments have repeatedly failed. The possibility that symptoms can change within hours or days rather than weeks is clinically important.

But ketamine remains a powerful medicine, not a guaranteed emotional breakthrough.

People respond differently. The experience may be profound, quiet, uncomfortable or difficult to interpret. Initial improvement may fade, and the longer-term role of repeated treatment still requires careful monitoring and further research.

The best way to understand ketamine is neither to idealise nor demonise it. It is to view it as one possible component of specialist treatment for carefully selected people.

Good treatment considers more than the medicine. It includes medical responsibility, psychological understanding, realistic expectations, honest discussion of risk and a plan for what happens after the immediate effects have passed.

Ketamine may make change feel more possible. Lasting recovery still has to be built within the person’s relationships, choices, routines and everyday life.

About This Article

This article provides general educational information about ketamine treatment, depression and psychotherapy. It does not recommend a particular prescription medicine or determine whether ketamine is suitable for any individual.

Ketamine treatment requires an individual assessment and a prescribing decision by an appropriately qualified medical professional.